



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

To,

Dated: 29.05.2018

The Manager,
Listing Department,
BSE Ltd.
P J Towers, Dalal Street,
Mumbai-400 001

Scrip Code: 524717

Sub: Outcome of Board Meeting for the Approval of Audited Financial Results for the quarter and year ended 31st March, 2018 and Recommendation of Dividend

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. **Tuesday, 29th May, 2018**, at the Corporate Office of the Company at **903-909, 9th Floor, BigJos Tower, Netaji Subhash Place, Delhi-110034**, have approved the Standalone and Consolidated Audited Financial Results for the quarter and year ended March 31st, 2018.

In terms of the Provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing the following:

- Audited Financial Results for the quarter and year ended 31st March, 2018
- Statement of Assets and Liabilities as on 31st March, 2018
- Auditors Report on the Audited Financial Results for the quarter and year ended 31st March, 2018,
- Declaration for Unmodified Opinion on Audit Report.

Further, the Board of Directors have recommended a dividend of Rs.0.75 per equity for the Financial Year ended on 31st March, 2018. The said dividend, if declared at the ensuing Annual General Meeting, will be credited/dispatched to the eligible shareholders after the AGM within the limit as prescribed under the Companies Act, 2013 and other applicable laws.


Kindly take the above in your record.

Thanking You,

Yours Sincerely,
For Titan Biotech Limited

Charanjit Singh

Charanjit Singh
Company Secretary



R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan
E-mail: marketing@titanbiotechltd.com
Website: www.titanbiotechltd.com | www.titanmedia.in



TITAN BIOTECH LTD.

AN ISO 9001:2015 CERTIFIED COMPANY



Office : 903-909, 9th Floor, Bigjos Tower, Netaji Subhash Place, Delhi-110034, India
Tel. : 011-27355742, 71239900 (44 Lines) | Fax : +91-11-47619811 | CIN: L74999RJ1992PLC013387

Dated: 29.05.2018

To,

The Manager-Corporate Services Department
BSE Limited
Jeejeebhoy Towers
Dalal Street,
Mumbai-400 001

Scrip Code: 524717

Sub: Declaration Pursuant to Regulation 33(3) (d) of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 for Unmodified Opinion

We hereby declare that the Statutory Auditors of the Company, M/s Sunita Agrawal & Co., Chartered Accountants (Firm Registration No. 515225C), have issued Audit Report with Unmodified Opinion on the Audited Financial Results of the Company for the financial year ended March 31st, 2018.


This declaration is given in compliance with Regulation 33(3) (d) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above in your record.

Thanking You,

Yours Faithfully
For Titan Biotech Limited

Prem Shankar Gupta
Chief Financial Officer



R.O. & Works: Unit I: A-902 A, RIICO Industrial Area, Phase-III, Bhiwadi-301019, Rajasthan
Unit II: E-540, Industrial Area, Chopanki, Bhiwadi-301019, Rajasthan

E-mail: marketing@titanbiotechltd.com

Website: www.titanbiotechltd.com | www.titanmedia.in



Auditor's Report on Quarterly and Annual Standalone Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have audited the accompanying Statement of Standalone Financial Results of **TITAN BIOTECH LIMITED** ("the Company") for the quarter and year ended **31st March, 2018** ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such standalone financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risks assessments, the auditor considers internal control relevant to the Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us is sufficient and appropriate to provide a reasonable basis for our audit opinion.



A-160, Upper Lobby Level,
Boulevard, Crown Plaza, Plot No. 13B,
Mayur Vihar Phase-1, Delhi-110092
Ph. : 011-49868379

1/35A, Lalita Park,
Near Gurudwara, Laxmi Nagar,
Delhi-110092
Ph. : 011-22455133

10, Giriraj Colony, Inside Fort
Bharatpur (Rajasthan)-321001
Ph. : 05644-225679
M : 9899567391

103-2B, Panorma Patliputra
CHS Oshiwara, Jogeshwari West
Mumbai (Maharashtra)-400102
M : 08898080517

E-mail : sunitaca_97@yahoo.com, sac.icai@gmail.com
Web. : www.consultants.tax

3. In our opinion and to the best of our information and according to the explanations given to us, the Statement:
- (a) is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/ FAC /62/2016 dated 5th July, 2016 in this regard; and
 - (b) gives a true and fair view in conformity with the aforesaid Indian Accounting Standards and other accounting principles generally in India of the net profit and total comprehensive income and other financial information of the Company for the quarter and year ended March 31, 2018.
4. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review.

For Sunita Agrawal & Co
Chartered Accountants
FRN: 515225C



(CA Sunita Agrawal)

Partner

M.No.095196

Place: Delhi
Date: 29th May, 2018



Auditor's Report on Quarterly and Annual Consolidated Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors of TITAN BIOTECH LIMITED

1. We have audited the accompanying Statement of Consolidated Financial Results of **TITAN BIOTECH LIMITED** ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the year ended **31st March, 2018** ("the Statement") being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016.

This Statement, which is the responsibility of the Holding Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our audit of such consolidated financial statements.

2. We conducted our audit in accordance with the Standards on Auditing issued by the Institute of Chartered Accountants of India. Those Standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the Statement is free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and the disclosures in the Statement. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the Statement, whether due to fraud or error. In making those risks assessments, the auditor considers internal control relevant to the Holding Company's preparation and fair presentation of the Statement in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Holding Company's internal control. An audit also includes evaluating the appropriateness of the accounting policies used and the reasonableness of the accounting estimates made by the Management, as well as evaluating the overall presentation of the Statement.

We believe that the audit evidence obtained by us and the audit evidence obtained by the other auditors in terms of their report referred in paragraph 4 below, is sufficient and appropriate to provide a reasonable basis for our audit opinion.



A-160, Upper Lobby Level,
Boulevard, Crown Plaza, Plot No. 13B,
Mayur Vihar Phase-1, Delhi-110092
Ph. : 011-49868379

1/35A, Lalita Park,
Near Gurudwara, Laxmi Nagar,
Delhi-110092
Ph. : 011-22455133

10, Giriraj Colony, Inside Fort
Bharatpur (Rajasthan)-321001
Ph. : 05644-225679
M : 9899567391

103-2B, Panorma Patliputra
CHS Oshiwara, Jogeshwari West
Mumbai (Maharashtra)-400102
M : 08898080517

E-mail : sunitaca_97@yahoo.com, sac.icai@gmail.com

Web : www.consultants.tax

3. In our opinion and to the best of our information and according to the explanations given to us, and based on the consideration of the reports of the other auditors on separate financial statements and other financial information of the Group and its subsidiary referred to in paragraph 5 below, the Statement:
- (a) includes the results of the following entities:
 - i) Subsidiary Company - M/s. Peptech Biosciences Limited
 - (b) is presented in accordance with the requirements of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No.CIR/CFD/ FAC /62/2016 dated 5th July, 2016 in this regard; and
 - (c) gives a true and fair view in conformity with the aforesaid Accounting Standards and other accounting principles generally in India of the net profit and total comprehensive income and other financial information of the Group for the quarter and year ended March 31, 2018.
4. We did not audit the financial statement of its subsidiary company included in the consolidated financial results, whose financial statements reflect total assets of Rs.448.26 Lakh as at March 31, 2018, total revenue of Rs.319.86 lakh, net profit of Rs.26.92 lakh for the year ended on that date, as considered in the consolidated financial results. These financial statements have been audited by the other auditor whose report have been furnished to us by the Management and our opinion on the consolidated financial results, in so far as it relates to the amounts and disclosures included in respect of this subsidiary, is based solely on the report of such other auditor.
- Our opinion on the Statement is not modified in respect of the above matters with respect to our reliance on the work done and the reports of the other auditors.
5. The comparative financial information for the quarter and year ended March 31, 2017 in respect of its subsidiary included in this Statement prepared in accordance with the Ind AS , have been audited by other auditor and have been relied upon by us.
6. The Statement includes the results for the Quarter ended March 31, 2018 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year, which were subject to limited review.



(CA Sunita Agrawal)

Partner

M.No.095196

Place: Delhi

Date: 29th May, 2018

S.NO.	PARTICULARS	(Rs. in lakhs) except for EPS											
		STANDALONE				CONSOLIDATED				YEAR ENDED			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
31.03.18	31.12.17	31.03.2017	31.03.18	31.03.17	31.03.18	31.12.17	31.03.2017	31.03.18	31.03.17	31.03.18	31.03.17		
AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	AUDITED	UNAUDITED	AUDITED	AUDITED	UNAUDITED	AUDITED	AUDITED		
	INCOME												
I	Revenue From operations	137.35	1490.52	1500.85	5553.15	5245.44	1507.40	1536.66	1505.63	5872.78	5273.61		
II	Other income	43.51	(1.67)	21.21	47.39	24.61	42.04	(0.09)	24.11	47.62	27.56		
III	Total income (+/-)	1420.86	1488.85	1522.06	5600.54	5270.05	1549.44	1536.77	1529.74	5920.40	5301.37		
IV	EXPENSES												
	Cost of materials consumed	698.82	663.64	1234.28	3922.05	4152.92	990.83	1046.32	1237.75	4159.70	4178.34		
	Purchases of Stock-in-Trade	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
	Changes in inventories of finished goods, Stock-in-Trade and work-in-progress	81.67	72.34	(129.77)	130.57	(160.36)	89.35	53.54	(129.77)	119.44	(160.36)		
	Employee benefits expense	82.17	77.13	96.67	307.42	276.84	99.31	85.76	104.30	348.25	289.37		
	Finance costs	61.89	57.29	45.27	235.21	146.58	63.66	57.33	46.04	238.93	147.58		
	Depreciation and amortization expenses	(6.42)	40.39	37.69	80.74	79.58	(8.01)	41.17	38.20	93.19	61.57		
	Other expenses	179.58	144.29	122.07	522.67	425.24	183.01	149.26	125.60	535.96	430.01		
	Total expenses (IV)	1305.71	1385.06	1405.20	5208.66	4920.80	1418.15	1433.38	1422.12	5465.47	4969.51		
V	Profit/(loss) before exceptional items and tax (III-IV)	115.15	103.77	115.86	391.88	349.25	131.29	103.39	107.62	424.93	334.86		
VI	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
VII	Profit/(loss) before exceptions items and tax(V-VI)	115.15	103.77	115.86	391.88	349.25	131.29	103.39	107.62	424.93	334.86		
VIII	Tax expense (1) Current tax(2) Deferred tax	(1.93)	25.40	19.19	107.97	115.61	(0.93)	25.51	19.55	114.17	118.78		
IX	Profit/(Loss) for the period from continuing operations (VII-VIII)	117.06	78.37	96.67	283.91	233.64	132.22	77.88	88.07	310.76	216.08		
X	Profit/(loss) from discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
XI	Tax expenses of discontinued operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
XII	Profit/(loss) from Discontinued operations (after tax) (X-XI)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
XIII	Profit/(loss) for the period (IX+XII)	117.06	78.37	96.67	283.91	233.64	132.22	77.88	88.07	310.76	216.08		
XIV	Other Comprehensive IncomeA: (i) Items that will not be reclassified to profit or loss(ii) Income tax relating to items that will not be reclassified to profit or loss B: (i) Items that will be reclassified to profit or loss(ii) Income tax relating to items that will be reclassified to profit or loss	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
XV	Total Comprehensive Income for the period (XIII+XIV)(Comprising Profit (Loss) and Other comprehensive Income for the period)	117.06	78.37	96.67	283.91	233.64	132.22	77.88	88.07	310.76	216.08		
XVI	Earnings per equity share (for continuing operation): (1) Basic(2) Diluted	1.51	1.01	1.25	3.67	3.02	1.71	1.01	1.14	4.02	2.82		
XVII	Earnings per equity share (for discontinued operation): (1) Basic(2) Diluted	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
XVIII	Earnings per equity share (for discontinued & continuing operation): (1) Basic(2) Diluted	1.51	1.01	1.25	3.67	3.02	1.71	1.01	1.14	4.02	2.82		



[Handwritten Signature]


The Statement of Assets and Liabilities as per Regulation 33 (3) (F) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015
(Rs. in Lakhs)

PARTICULARS	STANDALONE		CONSOLIDATED	
	YEAR ENDED 31.03.2018 (Audited)	YEAR ENDED 31.03.2017 (Audited)	YEAR ENDED 31.03.2018 (Audited)	YEAR ENDED 31.03.2017 (Audited)
A EQUITY AND LIABILITIES				
1. Shareholders Fund				
(a) Share Capital	773,870	773,870	773,870	773,870
(b) Reserve and Surplus	1753,765	1539,742	1768,147	1527,239
Sub total - Shareholders Fund	2527,635	2313,612	2542,017	2301,109
Minority Interest	0,000	0,000	112,506	112,506
2. Non-current Liabilities	1826,775	1477,959	1867,290	1517,416
(a) Long Term borrowings	65,873	60,116	68,482	61,974
(b) Deferred Tax Liabilities/(net)	0,000	0,000	0,000	0,000
(c) Other Long Term Liabilities	0,000	0,000	0,000	0,000
(d) Long Term Provisions	1760,902	1417,843	1798,808	1455,442
Sub total - Non Current Liabilities	1826,775	1477,959	1867,290	1517,416
3. Current Liabilities	710,161	726,142	710,161	726,142
(a) Short Term borrowings	106,336	116,366	237,792	140,225
(b) Trade Payables	168,262	161,054	202,154	186,152
(c) Other Current Liabilities	172,278	170,727	177,507	170,727
(d) Short Term Provisions	1177,036	1158,291	1327,614	1225,246
Sub total - Current Liabilities	4597,149	5049,976	5917,919	5218,263
TOTAL EQUITY & LIABILITIES				
B ASSETS				
1. Non Current Assets				
(a) Fixed Assets	1073,477	1068,665	1349,015	1261,936
(i) Tangible Assets	18,606	22,966	18,606	22,966
(ii) Intangible Assets	1327,907	928,924	1331,292	931,663
(iii) Cap. Work in progress	127,484	127,484	0,000	0,000
(b) Investment	53,945	46,598	54,187	117,893
(c) Long term Loans and Advance	0,000	0,000	0,893	1,191
(d) Other non-current assets	2601,428	2194,847	2753,963	2335,039
Sub total Non-Current Assets	1719,186	1439,173	1758,325	1449,925
2. Current Assets	803,615	627,451	906,606	634,431
(a) Inventories	118,855	422,204	124,121	429,839
(b) Trade Receivables	141,729	105,889	156,662	107,353
(c) Cash and cash equivalents	212,323	200,614	218,112	281,065
(d) Short Term Loan and Advances	2966,720	2855,331	3163,926	2882,614
(e) Other Current Assets	5597,149	5049,976	5917,919	5218,263
Sub total - Current Assets				
TOTAL ASSETS				

Notes:

- The above results for the quarter and year ended 31st March 2018 have been reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on 20th May 2018.
- The Statutory Auditors of the Company have conducted Audit of these financial results in terms of Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements), Regulations 2015. There are no qualification in the report issued by Auditors.
- The Board of Directors at their meeting considered and recommended dividend of Rs. 0.75 per equity share of Rs. 10/- each subject to the approval of the Shareholders in the Annual General Meeting of the Company. Results for the quarter and year ended 31st March 2018 are in compliance with the Indian Accounting Standards (Ind-AS) notified by the Ministry of Corporate Affairs. Consequently results for the quarter and year ended 31st March 2017 have been restated to comply with Ind-AS to make them comparable.
- Post the applicability of GST with effect from 1st July 2017, Sales are disclosed net of GST. Accordingly, the Gross sales figures for the year ended 31st March 2018 are not comparable with the sales figures depicted in the results for the previous periods.
- The Consolidated Results for the financial year ended 31st March 2018 include the results of its SUBSIDIARY COMPANY - PEPTECH BIOSCIENCES LIMITED.
- The Company has only one reportable business segment.
- Previous period figures are regrouped/reclassified in line with the current period.

Place : Delhi
Dated : 29.05.2018



For and on behalf of Board of Director
for TITAN BIOTECH LIMITED
Naresh Kumar Singla
NARESH KUMAR SINGLA
Managing Director

TITAN BIOTECH LIMITED

Regd. Office :- A-902 A RICO Industrial Area, Phase III, Bhiwadi, Rajasthan-301019
 Phone No. 011-71239900, Fax No. +91-11-47619811 Email : hrd@titanbiotechind.com www.titanbiotechind.com CIN : L74999RJ1992PLC013387
 STATEMENT OF AUDITED FINANCIAL RESULTS FOR THE QUARTER & YEAR ENDED 31ST MARCH, 2018

S.NO.	PARTICULARS	(Rs. in lakhs) except for EPS											
		STANDALONE						CONSOLIDATED					
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		31.03.18	31.12.17	31.03.2017	31.03.18	31.03.17	31.03.18	31.12.17	31.03.2017	31.03.18	31.03.17	31.03.18	31.03.17
AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	AUDITED	UNAUDITED	AUDITED	AUDITED	AUDITED	AUDITED	AUDITED		
1	Total Income from Operation (Net)	1420.86	1488.85	1522.08	5600.54	5770.05	1549.44	1536.77	1529.74	5920.40	5301.37		
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	115.15	103.77	115.96	391.88	349.25	131.29	103.39	107.62	424.93	354.86		
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	115.15	103.77	115.96	391.88	349.25	131.29	103.39	107.62	424.93	354.86		
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	117.08	78.37	96.67	283.91	233.64	132.22	77.88	88.07	310.76	218.08		
5	Total comprehensive income for the period (comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income/(after tax)(refer note 2)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
6	Paid-up Equity Share Capital (Face value of Rs. 10/- per share)	773.87	773.87	773.87	773.87	773.87	773.87	773.87	773.87	773.87	773.87	773.87	
7	Reserve excluding Revaluation Reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	1753.79	1539.74	0.00	0.00	0.00	1768.15	1527.24		
8	Earning Per Share												
	(a) Basic	1.51	1.01	1.25	3.67	3.02	1.71	1.01	1.14	4.02	2.82		
	(b) Diluted	1.51	1.01	1.25	3.67	3.02	1.71	1.01	1.14	4.02	2.82		

NOTES :

- The above is an extract of the detailed format of Audited Financial Results for the quarter & Year ended 31st March 2018 filed with the BSE Limited Under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Audited Financial Results for the said Quarter & Year ended 31st March 2018 are available on the website of BSE Limited at www.bseindia.com and on company website at www.titanbiotechind.com
- We declare that Statutory Auditors have furnished unmodified/unqualified audit report on the audited financial results for the quarter and year ended 31st March 2018.
- The financial results have been prepared in accordance with Indian Accounting Standards applicable with effect from 01.04.2017.
- Previous period figures are regrouped/reclassified in line with the current period.



For and on behalf of Board of Directors
 for TITAN BIOTECH LIMITED

NAREESH KUMAR SINGLA
 Managing Director

Place : Delhi
 Date : 29.05.2018

